Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018

Executive Summary

New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.

Advertisement

Related Content

42 New Substances Among 84 EU Approval Recommendations In 2018
New EU Approvals
Luxturna's EU Approval Highlights Gene Therapy Pricing Challenges
CAR-T Therapies Should Impress EU Reimbursement Bodies
Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up
14 Approvals To Look Out For In Q3
Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected
More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE
Seven New Drugs Approved In EU In First Two Months of 2018
All Systems Go as Roche MS Drug Ocrevus Secures EU Okay At Last

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel